Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Completed · Phase 4 · Has a placebo group

Conditions studied: Hypercholesterolemia

In brief

The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.

Key facts

Study ID
NCT02957682
Run by
Regeneron Pharmaceuticals
People needed
2176
Starts
2016-11-02
Expected to finish
2020-03-05
Last updated by the study team
2021-05-07

Who can join

Age: 40 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.